{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:50:54Z","timestamp":1791881454942,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cardfail.2026.02.038","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:28:46Z","timestamp":1773332926000},"page":"1778-1780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Amyloidosis Epidemiologic Paradox: Therapeutic Advances Amid Increasing Mortality"],"prefix":"10.1016","volume":"32","author":[{"given":"JENNA","family":"BILODEAU-GANDRE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAMELA","family":"FIELDS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CECELIA","family":"HERNANDEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5671-5596","authenticated-orcid":false,"given":"MELISSA A.","family":"LYLE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.02.038_bib0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0003","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2025.10.006","article-title":"Demographics and trends in reported amyloidosis-related mortality in the United States, 1999-2023","author":"Jaiswal","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cardfail.2025.07.007","article-title":"HF STATS 2025: heart failure epidemiology and outcomes statistics an updated 2025 report from the Heart Failure Society of America","volume":"32","author":"Writing Committee","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0008","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s12170-021-00670-y","article-title":"Racial and ethnic disparities in transthyretin cardiac amyloidosis","volume":"15","author":"Spencer-Bonilla","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13506129.2025.2462541","article-title":"Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium's treatment affordability patient and caregiver survey","volume":"32","author":"Rebello","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0011","article-title":"From the starting line- creating a multidisciplinary amyloidosis program: a practical guide","author":"Brailovsky","year":"2025","journal-title":"Cardiology: A Member Publication of the American College of Cardiology"},{"key":"10.1016\/j.cardfail.2026.02.038_bib0012","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Writing","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:23:40Z","timestamp":1791879820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1071916426001387"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.038","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Amyloidosis Epidemiologic Paradox: Therapeutic Advances Amid Increasing Mortality","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.10.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}